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SUMMARY
Background: Psychological factors may influence persistence and perceived severity of
symptoms in irritable bowel syndrome (IBS). Literature suggests that somatisation is
associated with IBS. However, the relationship between IBS subtype, symptoms of IBS, and
somatisation is unclear.
Aims:We examined this issue in a large cohort of secondary care patients.
Methods: Demographic and gastrointestinal (GI) symptom data were collected from 4224
adult patients via the Rome III questionnaire. Somatisation data were collected using the
patient health questionnaire-12. Mean somatisation score and number of somatic symptoms
were compared between IBS patients and controls with minimal GI symptoms, and between
IBS subtypes using analysis of variance. Effect of level of somatisation on symptom
IUHTXHQF\ZDVFRPSDUHGDFFRUGLQJWR,%6VXEW\SHXVLQJDȤ2 test.
Results: 840 patients met Rome III criteria for IBS, controls were 2137 patients with GI
symptoms without IBS. Mean somatisation scores and number of somatic symptoms were
higher in IBS versus controls (P < 0.001), and in mixed stool pattern IBS (IBS-M), versus
IBS with constipation (IBS-C) or diarrhoea (IBS-D) (P < 0.001). High levels of somatisation
were more prevalent in IBS-M (31.7%) versus IBS-C (22.5%) or IBS-D (20.8%) (P = 0.003).
For all IBS subtypes, high levels of somatisation were associated with a greater frequency of
bloating or abdominal distension prior to logistic regression.
Conclusions: IBS is strongly associated with higher levels of somatisation, particularly IBS-
M. Bloating may be associated with higher levels of somatisation, perhaps explaining why it
can be difficult to treat.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a functional lower gastrointestinal (GI) tract
disorder, with an estimated prevalence of between 10% and 20%.
1
The condition is
characterised by the presence of abdominal pain or discomfort accompanied by a change in
frequency and/or form of stool, in the absence of an organic cause.
2
The symptoms
experienced by IBS sufferers are not specific to the condition. Therefore, in order to
distinguish IBS from transient bowel symptoms or organic GI disorders, symptom-based
diagnostic criteria are used.
3
In addition to symptoms referable to the GI tract, psychological symptoms such as
anxiety, stress, or depression are also highly prevalent in patients with IBS.
4, 5
These
psychological factors may influence the persistence and perceived severity of symptoms.
6
This, coupled with evidence that treatments such as cognitive behavioural therapy (CBT) and
hypnotherapy are effective for the treatment of IBS,
7-9
further underlines the influence that
psychological factors may have in IBS.
Somatisation, defined as the reporting of physical bodily complaints in the absence of
a known medical cause, is another psychological condition that may co-exist with IBS.
10
Although previous studies have alluded to an association between somatisation and IBS,
there has been little research conducted to explore this relationship. In particular, there have
been few studies conducted since the revision of the Rome diagnostic criteria in 2006.
2
Furthermore, no study has examined whether the severity of somatisation varies between IBS
subtypes, or whether there is an association between reported frequency of GI symptoms and
severity of somatisation.
This highlights the need for a contemporaneous study examining the relationship
between IBS and somatisation. We have therefore examined this issue in a large cohort of
patients with Rome III-defined IBS, and a control group of patients with minimal GI
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symptoms. We postulated that the severity of somatisation would be greater in those with IBS
compared with controls, may vary between IBS subtypes, and that high levels of somatisation
would be associated with more frequent GI symptoms.
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MATERIALS AND METHODS
Participants and Setting
All individuals who participated in the study were newly referred from primary care
to secondary care for consideration of investigation of GI symptoms. Unselected consecutive
patients aged 16 years or over were recruited at two GI outpatient clinics at either McMaster
University Medical Center or St. Joseph’s Healthcare, two hospitals in Hamilton, Ontario,
Canada. These hospitals serve a local population of 520,000 people. The inability to
understand written English was the only exclusion criteria. At the first clinic visit, prior to the
consultation with a gastroenterologist, individuals were presented with a study information
sheet explaining the nature of the study. Patients who agreed to take part were asked to
provide written informed consent at this visit. This study was approved by both the Hamilton
Health Sciences and McMaster University research ethics boards in January 2008, and data
collection ceased in December 2012. We have previously used this dataset to validate the
Rome III criteria for functional dyspepsia and IBS, as well as to examine the characteristics
of patients meeting criteria for one of the functional bowel disorders.
11-13
Data Collection and Synthesis
Symptom and Demographic Data
Symptom and demographic data were collected at the first clinic appointment via a
questionnaire. Demographic data collected included gender, age, ethnicity, marital status,
educational level, tobacco and alcohol use, weight (in kilograms) and height (in meters),
which were used to calculate body mass index (BMI). Symptom data were collected using the
validated Rome III diagnostic questionnaire for adult functional GI disorders.
14
This
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questionnaire was used to record the frequency of individual lower GI symptoms, including
lower abdominal pain or discomfort, stool frequency, stool consistency, bloating or
abdominal distension, tenesmus, and urgency using a Likert scale. We used the validated
hospital anxiety and depression scale to collect information about mood.
15
This is a 14-item
instrument with seven questions concerning anxiety, and another seven that screen for the
presence of depression. Each of these individual questions is scored on a scale from 0 to 3,
giving a total possible score of 21 for anxiety or depression separately. We used a score of
RQHDFKRIWKHVHDVVXJJHVWHGE\WKHDXWKRUVWRFODVVLI\LQGLYLGXDOVDVH[KLELWLQJ
possible anxiety or depression.
Definition of IBS and Controls
The presence of IBS was defined using the Rome III criteria, with patients subdivided
by predominant stool pattern.
2
Constipation-predominant IBS (IBS-C) was defined when a
SDWLHQWUHSRUWHGOXPS\RUKDUGVWRROVRIWKHWLPHDQGZDWHU\RUORRVHVWRROVRI
the time. Diarrhoea-predominant IBS (IBS-D) was defined as hard or lumpy stools <25% of
WKHWLPHDQGZDWHU\RUORRVHVWRROVRIWKHWLPH0L[HGVWRROSDWWHUQ,%6,%60ZDV
GHILQHGZKHQVWRROVZHUHORRVHRUZDWHU\RIWKHWLPHDQGDOVRKDUGRUOXPS\RI
the time. Controls were all other patients referred with GI symptoms who did not meet the
Rome III criteria for IBS.
Definition of Somatisation Severity Using the Patient Health Questionnaire (PHQ)
Somatisation data were collected using the PHQ-15, which is derived from the
validated full PHQ.
16, 17
The PHQ-15 enquires about the presence of 15 somatic symptoms
(or symptom clusters) over the last 4 weeks, which are estimated to contribute to more than
90% of physical complaints reported in the outpatient environment.
18
However, three
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questions within the original PHQ-15 relate to the GI tract, and were therefore excluded to
avoid any overestimation of the severity of somatisation among a group of patients who were
already reporting GI symptoms, to form the PHQ-12 (Appendix 1). This approach has been
used by other investigators when examining somatisation among patients with GI
symptoms.
19
Each individual was asked to rate the severity of each symptom as “not bothered
at all” (scored as 0), “bothered a little” (scored as 1), or “bothered a lot” (scored as 2).
Therefore the total PHQ-12 score ranges from a minimum of 0 to a maximum of 24.
Somatisation severity was categorised, according to total PHQ-12 score, into high (total
3+4PHGLXPORZDQGPLQLPDOOHYHOVRIVRPDWLVDWLRQVHYHULW\
Statistical Analysis
The mean PHQ-12 score and the total number of individual somatic symptom items
reported were compared between patients with IBS and controls, as well as between IBS
subtypes (IBS-D, IBS-C and IBS-M) using one way analysis of variance. The number of
patients reporting each of the 12 individual somatic symptom items was compared between
those with IBS and controls. The number with a high level of somatisation severity was
compared between patients with IBS and controls, and according to presence of possible
anxiety or depression, and between IBS subtypes (IBS-D, IBS-C and IBS-M). Adjusted odds
ratios (ORs) with 99% confidence intervals (CIs) were calculated, in order to assess whether
the prevalence of higher levels of somatisation severity in IBS patients was greater compared
with controls, after controlling for differences in lifestyle and demographic variables, as well
as mood scores. These analyses were also performed according to IBS subtype. In addition,
the effect of level of somatisation on the frequency of individual IBS symptoms, including
lower abdominal pain or discomfort, stool frequency, stool consistency, bloating or
abdominal distension, tenesmus, and urgency were compared according to IBS subtype. All
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RIWKHVHFRPSDULVRQVZHUHFRQGXFWHGXVLQJDȤ2 test. Independent risk factors associated with
the frequency of these individual symptom items were determined by performing multivariate
logistic regression analysis to control for all lifestyle and demographic factors, as well as
mood scores. Due to multiple testing, a two tailed P value of < 0.01 was considered
statistically significant. All statistical analyses were performed using SPSS for Windows
version 20.0 (SPSS Inc, Chicago, IL, USA).
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RESULTS
A total of 4224 (70.7%) of 5978 patients attending the outpatient clinic gave informed
consent and were recruited into the study. Of these, 2977 provided complete somatisation
data, of whom 840 (28.2%) met the Rome III criteria for IBS (mean age 38.3 years (range 16-
89 years), 702 (83.6%) female). The control group consisted of 2137 patients without IBS
(mean age 48.3 years (range 16-91 years), 1397 (65.4%) female). Controls were significantly
older, less likely to be female, less likely to have never married, more likely to have only
been educated to high school level, and less likely to be smokers than those with IBS, and
had lower anxiety and depression scores (Table 1). Organic GI disease prevalence among
controls is provided in Supplementary Table 1 online. Of those who met Rome III criteria for
IBS, 289 (34.4%) had IBS-D, 138 (16.4%) IBS-C, and 413 (49.2%) IBS-M.
Prevalence of Individual PHQ-12 Somatic Symptom Items Among IBS Patients and
Controls
Nine of the 12 somatic symptom items listed on the PHQ-12 at a level of “bothered a
lot” were reported at a significantly greater frequency by IBS patients compared with controls
(Table 2). The commonest somatic symptom item reported among patients with IBS was
feeling tired or low in energy (582 (69.3%) individuals), followed by trouble sleeping (399
(47.5%) subjects), and back pain (313 (37.3%) patients). The only somatic symptom items
that were not significantly more common in IBS patients were chest pain, fainting spells, and
shortness of breath.
PHQ-12 Scores and Somatisation Severity Among IBS Patients and Controls
Distribution of PHQ-12 scores in patients with IBS and controls without is shown in
Figure 1. Mean PHQ-12 scores were significantly higher in IBS patients (9.7) compared with
Patel et al. 11 of 32
controls (6.8) (P <0.001) (Table 3). In addition, the total number of somatic symptom items
reported was significantly higher among IBS patients (n = 6.8) compared with patients in the
control group (n = 5.0) (P <0.001) (Table 3). When levels of somatisation were compared,
there were 222 (26.4%) IBS patients with a high level, compared with only 239 (11.2%)
FRQWUROVȤ2 for trend, P <0.001) (Table 3).
As the majority of patients with IBS were female, we examined somatisation levels
according to gender. There were 200 (28.5%) of 702 female patients with IBS with high
levels of somatisation, compared with 190 (13.6%) of 1397 (P <0.001). Among 138 male
patients with IBS, 22 (15.9%) demonstrated high levels of somatisation, compared with 49
(6.6%) of 740 male controls (P <0.001). After multivariate logistic regression controlling for
lifestyle and demographic variables, as well as mood scores, the prevalence of a medium or
high level of somatisation remained significantly higher among IBS patients (OR = 1.73;
99% CI 1.22 to 2.43). Among those with IBS, 818 provided complete anxiety data, 277
(33.9%) of whom exhibited possible anxiety. Of those with possible anxiety, 124 (44.8%)
had a high level of somatisation, compared with 91 (16.8%) of 541 without (P <0.001). There
were 813 IBS patients providing complete depression data. Of the 107 with possible
depression, 61 (57.0%) had a high level of somatisation, compared with 152 (21.5%) of 706
without (P <0.001).
PHQ-12 Scores and Somatisation Severity Among IBS Patients According to Subtype
When the effect of IBS subtype on somatisation was studied, mean PHQ-12 scores
were significantly higher in patients with IBS-M (10.4) compared with IBS-C (8.9), or IBS-D
(9.2) respectively (P <0.001) (Table 4). The total number of somatic symptom items reported
was also significantly higher in patients with IBS-M (n = 7.2), compared with IBS-C (n =
6.2), or IBS-D (n = 6.4) (P <0.001) (Table 4). Finally, when somatisation level was assessed
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according to IBS subtype, the prevalence of a high level of somatisation was significantly
greater in patients with IBS-M (131 patients (31.7%)) compared with IBS-C (31 patients
(22.5%)), or IBS-D (60 patients (20.8%)) (P = 0.003) (Table 4). After multivariate logistic
regression controlling for lifestyle and demographic variables, as well as mood scores, the
prevalence of a high level of somatisation remained significantly lower in those with IBS-D,
compared with IBS-M (OR = 0.49; 99% CI 0.28 to 0.88), but not IBS-C (OR = 0.65; 99% CI
0.30 to 1.38).
Relationship Between Symptom Frequency and High Levels of Somatisation
For all IBS subtypes, high levels of somatisation were associated with a significantly
greater frequency of bloating or abdominal distension (P <0.001 for IBS-M and IBS-D, and P
= 0.004 for IBS-C respectively) (Table 5). In terms of frequency of bloating across all three
subtypes, among those who provided complete data for this analysis there were 332 (81.8%)
of 406 IBS-M patients with bloating or distension often, most of the time, or always
compared with 207 (72.9%) of 284 patients with IBS-D, and 111 (81.0%) of 137 with IBS-C.
For patients with IBS-M, high levels of somatisation were also associated with a significantly
greater likelihood of reporting <3 stools per week (P = 0.001). No other significant
associations between high levels of somatisation and frequency of individual GI symptoms
were observed (Table 5), although the absolute numbers of individuals reporting many of the
symptoms at a greater frequency were generally higher among those who met criteria for a
high level of somatisation. However, after multivariate logistic regression, controlling for all
lifestyle and demographic factors, as well as mood scores, the observed association between
high levels of somatisation severity and frequency of bloating or reporting <3 stools per week
was no longer statistically significant.
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DISCUSSION
This study has demonstrated that patients with Rome III IBS had a higher prevalence
of somatisation, reported a greater number of somatic symptom items, and experienced a
greater severity of somatisation compared with controls without IBS. IBS patients also had a
significantly greater prevalence of almost all of the individual somatic symptom items. The
commonest somatic symptom item reported among patients with IBS was feeling tired or low
in energy. Mean somatisation scores, number of somatic symptom items, and prevalence of a
high level of somatisation severity were all significantly greater in IBS-M patients, compared
with IBS-C and IBS-D patients. When assessing whether individual GI symptoms worsened
with higher levels of somatisation, we found that there was a significantly greater frequency
of bloating or abdominal distension across all three subtypes of IBS in the presence of a
higher level of somatisation, but this was no longer the case after multivariate logistic
regression, although part of the explanation for this could be that due to incomplete data the
number of individuals in these analyses fell.
Strengths of this study include the large sample size, with almost 3000 participants.
Recruited patients were both consecutive and unselected, meaning that these results are likely
to be generalisable to usual clinical practice. We also used validated questionnaires to collect
data, including the Rome III diagnostic questionnaire for the adult functional GI disorders
and, to our knowledge, this is the first study of its kind to study the association between
somatisation and IBS using these criteria, which are the current gold-standard for diagnosing
IBS. Although the original PHQ-15 has been validated,
20
the derived PHQ-12 utilised in this
study has not been fully validated as screening tool for somatisation. However, Spiller et al.
used the PHQ-12 for assessing somatisation in IBS and diverticular disease patients,
19
and
found the PHQ-12 to be a useful clinical tool to assess patient behaviour. In addition, when
we repeated our analyses using the full PHQ-15, those with IBS demonstrated significantly
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higher PHQ-15 scores and a significantly greater prevalence of high levels of somatisation
severity, compared with controls, and those with IBS-M had significantly higher PHQ-15
scores and a significantly greater prevalence of high somatisation severity, compared with
those with IBS-D or IBS-C (see Supplementary Table 2 and 3 online). We also performed
multivariate logistic regression controlling for lifestyle and demographic variables, as well as
mood scores, and our observation that a higher level of somatisation occurred more
frequently in IBS patients compared with controls, and in IBS-M patients compared with
IBS-D, remained statistically significant.
There were weaknesses in this study. As this was a cross-sectional study, causality
cannot be implied by our results. Lower GI investigations were not mandated in order to
exclude the presence of an organic disease. This could mean that a proportion of both IBS
and control patients may have had an underlying pathology accounting for the symptoms they
were presenting with, resulting in some of the differences observed in demographic
characteristics and symptoms. As the PHQ-12 is a self-administered questionnaire this means
that, without clinical judgment, a distinction cannot be made between medically explained
and unexplained symptoms expressed within the questionnaire. Some somatic symptoms may
differ during different times, i.e. they may be present at a baseline level during the initial
primary care visit, but then disappear before the secondary care assessment. As 70.7% of
those approached agreed to take part in the study, there is also the possibility of selection
bias, although as studying the relationship between somatisation and IBS was not the primary
aim of this study we do not feel this is likely to have had any major impact on the results we
observed. Finally, as this study was conducted among a referral population, the results may
not be generalisable to subjects in the community.
The significantly higher somatisation scores and total number of somatic items, and
significantly greater prevalence of individual PHQ-12 somatic symptom items and high
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somatisation severity in IBS patients, compared with controls, observed in this study are in
line with other previous studies which have also shown an association between somatisation
and IBS.
10, 21-28
However, some of these studies only used somatisation as a controlling
personality variable when assessing its association with IBS,
27, 28
resulting in no data
comparing quantifiable levels of somatisation in IBS patients versus controls, an issue our
study was able to address. In addition, other studies could potentially have overestimated the
levels of somatisation in IBS,
24, 25
because they used the screening for somatoform
symptoms-7 questionnaire, in which 10 out of the 53 items are GI in nature,
29
and these were
not excluded in studies by the investigators. We excluded the three GI items in the original
PHQ-15 in order to avoid this overestimation. Therefore our study may have provided a more
realistic measure of the degree of association between IBS and somatisation.
There have been few studies comparing somatisation between IBS subtypes. Talley et
al. compared somatisation between IBS-C and IBS-D patients,
10
and found that there was no
difference between the two subtypes, utilising the Rome II criteria for IBS, which defines
those IBS patients with an alternating stool pattern as IBS-A, but chose to exclude these from
their analysis. Our study included data from all three subtypes of IBS allowing us to compare
somatisation levels between IBS-C, IBS-D and IBS-M. Other studies have also utilised the
now outdated Rome I or Rome II criteria,
21, 23
with some studies even using a combination of
Rome criteria to define IBS.
28
It should also be noted that there are varying prevalence rates
of IBS associated with the different revisions to the Rome diagnostic criteria.
30, 31
Our study
is also one of the few to examine the association between levels of somatisation and
frequency of individual reported IBS symptoms.
Our findings indicate that IBS-M patients experience a greater prevalence and
severity of somatisation. Reasons for this are unclear, but given that those with IBS-M have
to endorse more GI symptoms to meet criteria for this subtype, compared with their
Patel et al. 16 of 32
counterparts with either IBS-D or IBS-C, perhaps this is not unexpected. With no other
studies available to compare our findings with, more research needs to be done assessing and
quantifying the varying levels of somatisation between the three IBS subtypes we have
observed, and examining how this impacts on the natural history of the condition. The
increased frequency of bloating associated with higher levels of somatisation suggests that
there may be psychological factors that drive this commonly reported symptom, although this
is potentially at odds with the results from other investigators who have demonstrated
physiological abnormalities that may explain bloating in patients with IBS, including
abdomino-phrenic displacement, ventro-caudal redistribution of intestinal contents, and
impaired gas propulsion.
32, 33
Whatever the mechanism, most pharmalogical agents have
provided disappointing results in the treatment of bloating,
34
although newer drugs such as
linaclotide appear promising.
35, 36
Treatments such as hypnotherapy or CBT appearing to
have a greater impact on these symptoms,
37, 38
further highlighting the potential role that
psychological stressors may play in the generation of the symptom of bloating. However, an
alternative explanation could be that people who meet criteria for a high level of somatisation
are more likely to endorse more frequent symptoms across a range of systems, including
those that constitute IBS. To further our understanding of the role psychological factors may
play in IBS longitudinal studies examining these issues are required.
In summary, patients with IBS had higher levels of somatisation than patients without.
This may be partly explained by increased levels of anxiety and depression, which could
lower the threshold for somatisation behaviour, leading to increased awareness of any
physical symptoms. IBS-M patients report a greater level and severity of somatisation in
comparison to IBS-C and IBS-D patients. Furthermore, patients in all three subtypes of IBS
who had higher levels of somatisation reported a greater frequency of bloating, although after
controlling for all demographic data this was no longer signifcant. However, this could still
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be an indication of the role that psychological factors play in this commonly reported
symptom, and may partly explain why it can be difficult to treat.
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Table 1. Characteristics of 840 Patients Reporting Symptoms Compatible with IBS,
Compared with 2137 Controls.
*P value for independent samples tWHVWIRUFRQWLQXRXVGDWDDQG3HDUVRQȤ2 for comparison of
categorical data.
IBS Control P Value *
(n = 840) (n = 2137)
Mean age 38.3 48.3 <0.001
Number of females (%) 702 (83.6) 1397 (65.4) <0.001
White Caucasian ethnicity (%) 762 (90.7) 1906 (89.2) 0.63
Marital status (%)
Married or co-habiting
Divorced
Never married
Widowed
451 (53.7)
94 (11.2)
272 (32.4)
15 (1.8)
1300 (60.8)
236 (11.0)
475 (22.2)
106 (5.0) <0.001
Educational level (%)
Elementary
High school
College or technical school
University
Postgraduate
10 (1.2)
214 (25.5)
277 (33.0)
242 (28.8)
83 (9.9)
92 (4.3)
613 (28.7)
611 (28.6)
546 (25.5)
224 (10.5) <0.001
Alcohol user (%) 497 (59.2) 1234 (57.7) 0.46
Tobacco user (%) 214 (25.5) 376 (17.6) <0.001
Mean BMI 26.2 27.1 0.002
Mean HAD anxiety score 8.7 6.6 <0.001
Mean HAD depression score 5.6 4.0 <0.001
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Table 2. Prevalence of Individual PHQ-12 Somatic Symptom Items in 840 IBS Patients
Compared with 2137 Controls.
PHQ-12 somatic
symptom item
(“reported as bothered
a lot”)
IBS (n = 840) Controls (n = 2137) P value*
Back pain (%) 313 (37.3) 468 (21.9) <0.001
Arm, leg, or joint pain
(%)
292 (34.8) 534 (25.0) <0.001
Period pain or period
problems (%)†
166/702 (23.6) 169/1397 (12.1) <0.001
Headaches (%) 247 (29.4) 297 (13.9) <0.001
Chest pain (%) 76 (9.0) 137 (6.4) 0.02
Dizziness (%) 127 (15.1) 161 (7.5) <0.001
Fainting spells (%) 15 (1.8) 32 (1.5) 0.69
Heart pounding or
racing (%)
103 (12.3) 130 (6.1) <0.001
Shortness of breath (%) 93 (11.1) 184 (8.6) 0.04
Pain or problems
during intercourse (%)
96 (11.4) 99 (4.6) <0.001
Tired or low in energy
(%)
582 (69.3) 883 (41.3) <0.001
Trouble sleeping (%) 399 (47.5) 659 (30.8) <0.001
3YDOXHIRU3HDUVRQȤ2.
†Female patients only
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Table 3. Somatisation Levels and Severity in 840 IBS Patients Compared with 2137
Controls.
IBS (n = 840) Controls (n = 2137) P value*
Mean PHQ-12 score
(SD)
9.7 (4.6) 6.8 (2.6) <0.001
Mean number of
somatic symptom items
reported (SD)
6.8 (2.6) 5.0 (2.7) <0.001
Level of somatisation
severity†
Minimal
Low
Medium
High
59 (7.0)
228 (27.1)
331 (39.4)
222 (26.4)
552 (25.8)
748 (35.0)
598 (28.0)
239 (11.2) <0.001
3YDOXHIRURQHZD\DQDO\VLVRIYDULDQFHRU3HDUVRQȤ2 test for trend.
†The total PHQ-12 score ranges from a minimum of 0 to a maximum of 24.
Somatisation severity was categorised, according to total PHQ-12 score, into high (total
3+4PHGLXPORZDQGPLQLPDOOHYHOVRIVRPDWLVDWLRQVHYHULW\
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Table 4. Somatisation Levels and Severity in 840 IBS Patients According to IBS
Subtype
IBS-M
(n = 413)
IBS-C
(n = 138)
IBS-D
(n = 289)
P value*
Mean PHQ-12 score
(SD)
10.4 (4.5) 8.9 (4.8) 9.2 (4.4) <0.001
Mean number of
somatic symptom
items reported (SD)
7.2 (2.5) 6.2 (2.8) 6.4 (2.6) <0.001
Level of somatisation
severity†
Minimal
Low
Medium
High
18 (4.4)
104 (25.2)
160 (38.7)
131 (31.7)
14 (10.1)
45 (32.6)
48 (34.8)
31 (22.5)
27 (9.3)
79 (27.3)
123 (42.5)
60 (20.8) 0.003
3YDOXHIRURQHZD\DQDO\VLVRIYDULDQFHRU3HDUVRQȤ2 test for trend.
†The total PHQ-12 score ranges from a minimum of 0 to a maximum of 24.
Somatisation severity was categorised, according to total PHQ-12 score, into high (total
3+4PHGLXPORZDQGPLQLPDOOHYHOVRIVRPDWLVDWLRQVHYHULW\
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Table 5. Prevalence of Individual IBS Symptom Items in the Presence of High
Somatisation Severity for 840 Patients Reporting Symptoms Compatible with IBS,
According to IBS Subtype.
IBS Subtype Somatisation Severity† P Value
High
Somatisation
Severity Absent
High
Somatisation
Severity Present
Bloating or distension often,
most of the time, or always
(%)
IBS-C (n=137) 82/106 (77.4) 29/31 (93.5) 0.004
IBS-M (n=406) 214/276 (77.5) 118/130 (90.8) <0.001
IBS-D (n=284) 152/224 (67.9) 55/60 (91.7) <0.001
Tenesmus often, most of the
time, or always (%)
IBS-C (n=138) 73/107 (68.2) 28/31 (90.3) 0.067
IBS-M (n=413) 161/282 (57.1) 86/131 (65.6) 0.018
IBS-D (n=288) 103/228 (45.2) 37/60 (61.7) 0.024
Urgency often, most of the
time, or always (%)
IBS-C (n=135) 10/106 (9.4) 4/29 (13.8) 0.048
IBS-M (n=412) 129/281 (45.9) 79/131 (60.3) 0.482
IBS-D (n=287) 149/227 (65.6) 50/60 (83.3) 0.038
Harder stools when pain
starts often, most of the
time, or always (%)
IBS-C (n=137) 52/107 (48.6) 17/30 (56.7) 0.939
IBS-M (n=409) 44/280 (15.7) 29/129 (22.5) 0.075
IBS-D (n = 287) N/A* N/A* N/A*
VWRROVSHUZHHNRI
the time (%)
IBS-C (n=138) 52/107 (48.6) 24/31 (77.4) 0.054
IBS-M (n=413) 55/282 (19.5) 43/131 (32.8) 0.001
IBS-D (n = 287) N/A* N/A* N/A*
Looser stools when pain IBS-C (n = 138) N/A* N/A* N/A*
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†The total PHQ-12 score ranges from a minimum of 0 to a maximum of 24.
Somatisation severity was categorised, according to total PHQ-12 score, into high (total
3+4PHGLXPORZDQGPLQLPDOOHYHOVRIVRPDWLVDWLRQVHYHULW\
starts often, most of the
time, or always
IBS-M (n=410) 143/280 (51.1) 63/130 (48.5) 0.332
IBS-D (n=287) 184/227 (81.1) 45/60 (75.0) 0.575
!VWRROVSHUGD\RI
the time
IBS-C (n = 138) N/A* N/A* N/A*
IBS-M (n=410) 89/279 (31.9) 39/131 (29.8) 0.796
IBS-D (n=287) 126/227 (55.5) 37/60 (61.7) 0.235
* N/A = not applicable. Could not endorse this symptom in order to meet criteria for this IBS
subtype.
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Figure 1. Distribution of PHQ-12 Scores Among 840 IBS Patients Compared with 2137 Controls.
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